- Home
- PMCB vs GTBP Comparison
PMCB vs GTBP Comparison
Compare PMCB & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- GTBP
- Stock Information
- Founded
- PMCB 1996
- GTBP 1965
- Country
- PMCB United States
- GTBP United States
- Employees
- PMCB N/A
- GTBP N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- GTBP Health Care
- Exchange
- PMCB Nasdaq
- GTBP Nasdaq
- Market Cap
- PMCB 6.6M
- GTBP 5.5M
- IPO Year
- PMCB N/A
- GTBP N/A
- Fundamental
- Price
- PMCB $0.94
- GTBP $0.95
- Analyst Decision
- PMCB
- GTBP Strong Buy
- Analyst Count
- PMCB 0
- GTBP 1
- Target Price
- PMCB N/A
- GTBP $11.00
- AVG Volume (30 Days)
- PMCB 118.7K
- GTBP 292.5K
- Earning Date
- PMCB 09-12-2025
- GTBP 08-14-2025
- Dividend Yield
- PMCB N/A
- GTBP N/A
- EPS Growth
- PMCB N/A
- GTBP N/A
- EPS
- PMCB 3.19
- GTBP N/A
- Revenue
- PMCB N/A
- GTBP N/A
- Revenue This Year
- PMCB N/A
- GTBP N/A
- Revenue Next Year
- PMCB N/A
- GTBP N/A
- P/E Ratio
- PMCB $0.30
- GTBP N/A
- Revenue Growth
- PMCB N/A
- GTBP N/A
- 52 Week Low
- PMCB $0.80
- GTBP $0.88
- 52 Week High
- PMCB $2.42
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- PMCB 47.20
- GTBP 26.68
- Support Level
- PMCB $0.92
- GTBP $0.88
- Resistance Level
- PMCB $1.00
- GTBP $0.99
- Average True Range (ATR)
- PMCB 0.09
- GTBP 0.10
- MACD
- PMCB 0.00
- GTBP 0.01
- Stochastic Oscillator
- PMCB 28.69
- GTBP 9.92
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.